Supplementary Figure 4 from SIRT1 Pathway Dysregulation in the Smoke-Exposed Airway Epithelium and Lung Tumor Tissue

Abstract

<p>PDF file, 72 K, SIRT1 pathway activation in lung tumor tissue datasets with smoking-status or different tumor subtypes. A. Lung tumor tissue (n=60, 56 adenocarcinomas, 1 squamous, 3 bronchioloalveolar carcinoma) and paired adjacent normal lung tissue (n=60) (GSE19804) from non-smoking women in Taiwan hybridized to Affymetrix HGU133 Plus 2.0 microarrays. There was no different between SIRT1 pathway activation between adjacent normal and tumor tissue. B. Top left. Adjacent normal lung tissue and paired lung tumor tissue (n=42 pairs, n=22 adenocarcinoma, n=9 large cell carcinoma, and n=11 squamous cell carcinoma) (GSE19188) hybridized to Affymetrix HGU133 Plus 2.0 microarrays. SIRT1 pathway activation was decreased between adenocarcinomas and normal lung tissue (ADC, p=0.044) and between large cell carcinomas and normal lung tissue (LCC, p=0.002); however, SIRT1 pathway activation was significantly increased in squamous cell carcinoma compared to adjacent normal lung tissue (SCC, p=0.023). Top middle. Adenocarcinoma (ADC, n=40) and squamous cell carcinoma (SCC, n=18) lung tumor tissue (GSE10245) was hybridized to Affymetrix HGU133 Plus 2.0 microarrays. SIRT1 pathway activation was significantly higher in SCC versus ADC tumors (p<0.001). Top right. Adenocarcinoma (ADC, n=50), large cell carcinoma (LCC, n=20), and squamous cell carcinoma (SCC, n=28) lung tumor tissue (GSE28571) was hybridized to Affymetrix HGU133 Plus 2.0 microarrays. SIRT1 pathway activation was significantly higher in SCC versus ADC tumors (p<0.001). Bottom left. Adenocarcinoma (ADC, n=58) and squamous cell carcinoma (SCC, n=53) lung tumor tissue (GSE3141) was hybridized to Affymetrix HGU133 Plus 2.0 microarrays. SIRT1 pathway activation is significantly lower in ADC versus SCC tumors (p<0.001). Bottom middle. CCLE lung cancer cell lines (n=180) that include n=49 adenocarcinoma (ADC), n=5 bronchioloalveolar adenocarcinoma (BAC), n=14 large cell carcinoma (LCC) , n=4 mixed adenosquamous carcinoma (Mixed ADC/SCC), n=1 mucoepidermoid carcinoma (mucoepidermoid), n=24 non-small cell carcinoma (NSCLC), n=53 small cell carcinoma (SCLC), n=26 squamous cell carcinoma (SCC), n=1 undifferentiated carcinoma (UnDiff), and n=3 Unknown.</p>